NDABUCCALGUM, CHEWING
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NICORETTE (MINT) is a nicotine polacrilex chewing gum formulation designed to deliver nicotine through the buccal mucosa as a smoking cessation aid. It functions as a cholinergic nicotinic agonist, replacing cigarette-derived nicotine to reduce withdrawal symptoms and cravings. The product has been a cornerstone of over-the-counter nicotine replacement therapy (NRT) since its approval in 1992.
LOE Approaching1.9 years to LOE
As a mature OTC product approaching loss of exclusivity in 2028, the brand team is likely focused on defensive positioning and cost management rather than aggressive growth initiatives.
Mechanism of Action
Pharmacologic Class:
Cholinergic Nicotinic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on NICORETTE (MINT) at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.